I’m wondering if any studies explain this and what’s the best way to address it. Should I increase the dose further or switch ...

Alabama now provides partial GLP-1 coverage for obesity: Among the obesity-indicated GLP-1s, Medicaid in Alabama covers just ...

A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...

The weight-loss market began feeling some growing pains as the year ended, creating more wariness for the upcoming year. For 2025, competition and supply constraints are areas to watch.

Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

New Delhi: Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and ...

Junk food companies are starting to get nervous over how many Americans use GLP-1 medications to lose weight. Washington Post ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

The holidays can be a difficult time for those with a history of eating disorders, and having someone comment on their body – ...

Drugs are arriving that cure the urge to overeat, drink and smoke. Thank goodness for that - it's time to stop blaming humans ...

After about 10 months of being on Ozempic and working my way up to a 1-mg dose, I lost 40 pounds effortlessly. Sugar cravings disappeared as if by magic. I then noticed myself drifting backward and ...